Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
kathryn_edwards [2022/05/16 07:48] liam | kathryn_edwards [2022/05/16 08:32] (current) liam |
---|
{{ ::edwardsk_0.jpeg?150|}} | {{ ::edwardsk_0.jpeg?150|}} |
| |
Dr. **Kathryn Edwards**, MD is an American pediatric infectious diseases specialist based in [[united_states_of_america:Tennessee:Nashville]], [[united_states_of_america:Tennessee]]. | Dr. **Kathryn M. Edwards**, MD is an American pediatric infectious diseases specialist based in [[united_states_of_america:Tennessee:Nashville]], [[united_states_of_america:Tennessee]]. |
| |
| ===== Career and Affiliations ===== |
| |
| ==== Vanderbilt University ==== |
| |
| Edwards is a professor of pediatrics in the division of [[infectious diseases]] at [[Vanderbilt University School of Medicine]], where she is also vice-chair for clinical research.((//Kathryn M. Edwards, M.D.// Vanderbilt Institute for Infection, Immunology and Inflammation. Retrieved May 15, 2022, from https://archive.ph/ngA4g)) |
| |
| ==== Pfizer ==== |
| |
| In September 2020, a [[CBS News]] article revealed that Edwards was a member of the [[Data and Safety Monitoring Board]] (DSMB) for [[pharmaceutical_companies:Pfizer]]'s BNT162 [[COVID-19 vaccines|COVID-19 vaccine]] trial.((McNamara, A. (2020, September 30). //When will a coronavirus vaccine really be ready?// CBS News. https://archive.ph/NjhWc)) |
| |
| ===== Research ===== |
| |
| Edwards has received research funding from the [[National Institutes of Health]] (NIH), the [[Center for disease control and prevention|Centres for Disease Control and Prevention]] (CDC), and [[IBM]].((Permar, S., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021). //Proposals to Accelerate Novel Vaccine Development for Children.// Pediatrics, 149(1). https://doi.org/10.1542/peds.2021-054593)) |
| |
| ==== Pharmaceutical Companies ==== |
| |
| Edwards has worked as a paid advisor for [[pharmaceutical_companies:Pfizer]], and has also received payments, speaking fees, or funding from numerous pharmaceutical companies, including [[pharmaceutical_companies:Moderna]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:X-4 Pharma]], [[medical_technology_companies:Bionet]], [[pharmaceutical_companies:Seqirus]], [[pharmaceutical_companies:Roche]], and [[pharmaceutical_companies:Smith-Kline Beecham]], and travel benefits from [[pharmaceutical_companies:Sanofi]].((//Conflicts of Interest in Pfizer Vaccine Trial.// (2022, April 12). ICAN - Informed Consent Action Network. https://archive.ph/qyGC6)) ((Permar, S., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021). //Proposals to Accelerate Novel Vaccine Development for Children.// Pediatrics, 149(1). https://doi.org/10.1542/peds.2021-054593)) |
| |